JP2024505250A - Ｇｐｃｒ受容体アゴニスト、それを含む医薬組成物、及びそれらの使用方法 - Google Patents

Ｇｐｃｒ受容体アゴニスト、それを含む医薬組成物、及びそれらの使用方法 Download PDF

Info

Publication number
JP2024505250A
JP2024505250A JP2023546234A JP2023546234A JP2024505250A JP 2024505250 A JP2024505250 A JP 2024505250A JP 2023546234 A JP2023546234 A JP 2023546234A JP 2023546234 A JP2023546234 A JP 2023546234A JP 2024505250 A JP2024505250 A JP 2024505250A
Authority
JP
Japan
Prior art keywords
alkyl
methyl
certain embodiments
substituted
xxx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023546234A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024505250A5 (https=
JPWO2022165076A5 (https=
Inventor
シャオフイ ドゥ，
レイ フチーニ，
シュー ラン，
チェン－フン イェ，
シャン ジョウ，
ルイ ガオ，
ジュン ウォン ジョン，
リー リウ，
スバス マン サクヤ，
シャオファン ワン，
洋幸 河合
クレイグ リー，
デイビッド ロイド，
スティグ ハンセン，
Original Assignee
カーモット セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カーモット セラピューティクス インコーポレイテッド filed Critical カーモット セラピューティクス インコーポレイテッド
Publication of JP2024505250A publication Critical patent/JP2024505250A/ja
Publication of JP2024505250A5 publication Critical patent/JP2024505250A5/ja
Publication of JPWO2022165076A5 publication Critical patent/JPWO2022165076A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023546234A 2021-01-28 2022-01-27 Ｇｐｃｒ受容体アゴニスト、それを含む医薬組成物、及びそれらの使用方法 Pending JP2024505250A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163143025P 2021-01-28 2021-01-28
US63/143,025 2021-01-28
US202163183612P 2021-05-03 2021-05-03
US63/183,612 2021-05-03
US202163274893P 2021-11-02 2021-11-02
US63/274,893 2021-11-02
PCT/US2022/014156 WO2022165076A1 (en) 2021-01-28 2022-01-27 Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use

Publications (3)

Publication Number Publication Date
JP2024505250A true JP2024505250A (ja) 2024-02-05
JP2024505250A5 JP2024505250A5 (https=) 2025-01-31
JPWO2022165076A5 JPWO2022165076A5 (https=) 2025-01-31

Family

ID=80447497

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023546234A Pending JP2024505250A (ja) 2021-01-28 2022-01-27 Ｇｐｃｒ受容体アゴニスト、それを含む医薬組成物、及びそれらの使用方法

Country Status (17)

Country Link
US (4) US20230089073A1 (https=)
EP (2) EP4284795A1 (https=)
JP (1) JP2024505250A (https=)
KR (1) KR20230152011A (https=)
AU (1) AU2022212019A1 (https=)
BR (1) BR112023015045A2 (https=)
CA (1) CA3209593A1 (https=)
CL (2) CL2023002204A1 (https=)
CO (1) CO2023011071A2 (https=)
CR (1) CR20230330A (https=)
EC (1) ECSP23057029A (https=)
GE (1) GEAP202316333A (https=)
IL (1) IL304521A (https=)
JO (1) JOP20230167A1 (https=)
MX (1) MX2023008854A (https=)
PE (1) PE20231814A1 (https=)
WO (1) WO2022165076A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI4143183T3 (fi) 2020-04-29 2026-01-07 Gasherbrum Bio Inc Heterosyklisiä glp-1-agonisteja
PE20231181A1 (es) 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos
WO2022042691A1 (en) * 2020-08-28 2022-03-03 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
IL310377A (en) * 2021-08-30 2024-03-01 Mindrank Ai Ltd Novel aryl ether substituted heterocyclic compound as glp1r agonist
KR20240068737A (ko) 2021-09-27 2024-05-17 테른스 파마슈티칼스, 인크. Glp-1r 효능제로서의 벤즈이미다졸 카복실산
WO2023057429A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
AU2022358915A1 (en) 2021-10-05 2024-05-09 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators
WO2023057414A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
AU2022375634A1 (en) 2021-10-25 2024-06-06 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
WO2023111145A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
US20250066338A1 (en) 2021-12-16 2025-02-27 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
KR20240150488A (ko) 2022-02-23 2024-10-15 테른스 파마슈티칼스, 인크. Glp-1r 작용제로서의 화합물
CN117362282B (zh) * 2022-07-07 2026-04-21 杭州德睿智药科技有限公司 Glp-1r激动剂的盐及其制备方法和应用
AU2023310481A1 (en) * 2022-07-18 2025-03-06 Mindrank Therapeutics (Suzhou) New Drug Research And Development Co., Ltd Polymorphic form of glp-1r agonist, preparation method therefor and use thereof
CN119923395A (zh) * 2022-07-27 2025-05-02 卡莫特医疗有限公司 N-杂环gpcr受体激动剂、包含其的药物组合物和其使用方法
WO2024051700A1 (zh) * 2022-09-05 2024-03-14 德睿智药(苏州)新药研发有限公司 作为glp1r激动剂的新型芳基氘代苄醚取代杂环类化合物
IL319453A (en) * 2022-09-06 2025-05-01 Mindrank Therapeutics Suzhou New Drug Res And Development Co Ltd Polymorph of a GLP-1R agonist compound, method of preparation thereof and use thereof
CN116102543B (zh) * 2022-10-21 2025-07-22 江南大学 一种glp-1r激动剂、合成方法及其用途
WO2024102625A1 (en) 2022-11-11 2024-05-16 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
IL320810A (en) 2022-11-16 2025-07-01 Lilly Co Eli Glucagon-like peptide 1 receptor agonists
CN120693338A (zh) * 2022-12-22 2025-09-23 加舒布鲁姆生物公司 杂环的glp-1激动剂
WO2024153041A1 (zh) * 2023-01-19 2024-07-25 杭州德睿智药科技有限公司 Glp-1r激动剂的制造方法与中间体及其用途
US20240398794A1 (en) 2023-04-07 2024-12-05 Terns Pharmaceuticals, Inc. COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF
TW202521533A (zh) 2023-09-14 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
WO2025128564A1 (en) 2023-12-11 2025-06-19 Carmot Therapeutics, Inc. Salt forms of a glp-1 receptor modulator
WO2025128561A1 (en) 2023-12-11 2025-06-19 Carmot Therapeutics, Inc. Crystalline forms of a glp-1 receptor modulator
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss
WO2025259888A1 (en) 2024-06-13 2025-12-18 Carmot Therapeutics Inc. Method of treating diabetes using a glp-1 receptor agonist
WO2026047102A1 (en) 2024-08-29 2026-03-05 F. Hoffmann-La Roche Ag Process for the preparation of pyrimidine derivatives

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190382384A1 (en) * 2018-06-13 2019-12-19 Pfizer Inc. GLP-1 Receptor Agonists and Uses Thereof
WO2020103815A1 (en) * 2018-11-22 2020-05-28 Qilu Regor Therapeutics Inc. Glp-1r agonists and uses thereof
WO2020207474A1 (en) * 2019-04-12 2020-10-15 Qilu Regor Therapeutics Inc. Glp-1r agonists and uses thereof
JP2023502081A (ja) * 2019-11-15 2023-01-20 イルドン ファーマシューティカル カンパニー リミテッド Ｇｌｐ－１受容体アゴニストおよびその使用
JP2023520003A (ja) * 2020-04-03 2023-05-15 江蘇恒瑞医薬股▲ふん▼有限公司 縮合イミダゾール誘導体、その調製方法及びその医薬的応用
JP2023524493A (ja) * 2020-04-29 2023-06-12 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
JP2023538408A (ja) * 2020-08-21 2023-09-07 ターンズ・ファーマシューティカルズ・インコーポレイテッド Ｇｌｐ－１ｒ作動薬としての化合物
JP2023538949A (ja) * 2020-08-28 2023-09-12 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
JP2023539584A (ja) * 2020-09-01 2023-09-15 江蘇恒瑞医薬股▲ふん▼有限公司 縮合イミダゾール誘導体、その調製方法及びその医薬的応用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2004613A2 (en) * 2006-03-31 2008-12-24 AstraZeneca AB Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators
CN101553483B (zh) * 2006-12-13 2013-04-17 弗·哈夫曼-拉罗切有限公司 作为非核苷逆转录酶抑制剂的2-(哌啶-4-基)-4-苯氧基-或苯基氨基-嘧啶衍生物
EP3555064B9 (en) * 2016-12-16 2023-03-01 Pfizer Inc. Glp-1 receptor agonists and uses thereof
US10954221B2 (en) 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
WO2020234726A1 (en) 2019-05-20 2020-11-26 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
TWI751585B (zh) 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
IL310377A (en) 2021-08-30 2024-03-01 Mindrank Ai Ltd Novel aryl ether substituted heterocyclic compound as glp1r agonist

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190382384A1 (en) * 2018-06-13 2019-12-19 Pfizer Inc. GLP-1 Receptor Agonists and Uses Thereof
WO2020103815A1 (en) * 2018-11-22 2020-05-28 Qilu Regor Therapeutics Inc. Glp-1r agonists and uses thereof
WO2020207474A1 (en) * 2019-04-12 2020-10-15 Qilu Regor Therapeutics Inc. Glp-1r agonists and uses thereof
JP2023502081A (ja) * 2019-11-15 2023-01-20 イルドン ファーマシューティカル カンパニー リミテッド Ｇｌｐ－１受容体アゴニストおよびその使用
JP2023520003A (ja) * 2020-04-03 2023-05-15 江蘇恒瑞医薬股▲ふん▼有限公司 縮合イミダゾール誘導体、その調製方法及びその医薬的応用
JP2023524493A (ja) * 2020-04-29 2023-06-12 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
JP2023538408A (ja) * 2020-08-21 2023-09-07 ターンズ・ファーマシューティカルズ・インコーポレイテッド Ｇｌｐ－１ｒ作動薬としての化合物
JP2023538949A (ja) * 2020-08-28 2023-09-12 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
JP2023539584A (ja) * 2020-09-01 2023-09-15 江蘇恒瑞医薬股▲ふん▼有限公司 縮合イミダゾール誘導体、その調製方法及びその医薬的応用

Also Published As

Publication number Publication date
CO2023011071A2 (es) 2023-11-10
US12459929B2 (en) 2025-11-04
IL304521A (en) 2023-09-01
CL2024002388A1 (es) 2025-01-24
AU2022212019A1 (en) 2023-08-03
CL2023002204A1 (es) 2024-03-01
PE20231814A1 (es) 2023-11-16
EP4563199A3 (en) 2025-08-06
JOP20230167A1 (ar) 2023-07-26
CA3209593A1 (en) 2022-08-04
EP4284795A1 (en) 2023-12-06
WO2022165076A1 (en) 2022-08-04
EP4563199A2 (en) 2025-06-04
BR112023015045A2 (pt) 2023-10-03
MX2023008854A (es) 2023-10-17
US20250092025A1 (en) 2025-03-20
KR20230152011A (ko) 2023-11-02
CR20230330A (es) 2023-11-15
US20240252492A1 (en) 2024-08-01
US20230089073A1 (en) 2023-03-23
US20250154137A1 (en) 2025-05-15
AU2022212019A9 (en) 2024-10-17
GEAP202316333A (en) 2023-12-11
ECSP23057029A (es) 2023-10-31

Similar Documents

Publication Publication Date Title
JP2024505250A (ja) Ｇｐｃｒ受容体アゴニスト、それを含む医薬組成物、及びそれらの使用方法
JP2024516291A (ja) ベンゾイミダゾイルｇｌｐ－１受容体アゴニスト、それを含む医薬組成物、及びそれらの使用方法
JP7017521B2 (ja) アクチビン受容体様キナーゼの阻害剤
TWI843104B (zh) 類升糖素肽1受體促效劑
JP2025525010A (ja) Ｎ－ヘテロ環式ｇｐｃｒ受容体アゴニスト、それを含む医薬組成物、及びそれらの使用方法
CN114728940A (zh) Glp-1受体激动剂及其用途
TW201102393A (en) Bridged bicyclic heterocycle derivatives and methods of use thereof
IL300610A (en) Bicycloheptane pyrrolidine compounds are orexin receptor agonists
CN117015526B (zh) 作为食欲素受体激动剂的芳基磺酰胺
CN117043154A (zh) Gpcr受体激动剂、包含其的药物组合物以及它们的使用方法
JP2024508769A (ja) Ｗｅｅ－１阻害剤としてのピリミジン化合物
CN117545748A (zh) 苯并咪唑基glp-1gpcr受体激动剂、包含其的药物组合物以及它们的使用方法
EA051557B1 (ru) Агонисты рецепторов gpcr, содержащие их фармацевтические композиции, и способы их применения
JP5950239B2 (ja) Ｍｃｈ−受容体モジュレーターとしてのピリジノン誘導体及びピリダジノン誘導体
HK40104123A (zh) Gpcr受体激动剂、包含其的药物组合物以及它们的使用方法
HK40107978A (zh) 苯并咪唑基glp-1gpcr受体激动剂、包含其的药物组合物以及它们的使用方法
HK40120799A (zh) N-杂环gpcr受体激动剂、包含其的药物组合物和其使用方法
WO2025222008A1 (en) Glucagon receptor agonists and their use as therapies
HK40072747A (en) Glp-1 receptor agonist and use thereof
HK40067799B (zh) 芳香杂环衍生物作为免疫调节剂的制备及其应用

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20241030

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250122

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260218